Results 201 to 210 of about 60,658 (250)

The Trojan horse of off-label glucagon-like peptide-1 receptor agonist use: Protecting patients through responsible practice. [PDF]

J Int Med Res
Belančić A, Jelaković B.
europepmc   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. [PDF]

Front Immunol
Ciancio G, Maranini B, Sandri G, Amati G, Bortoluzzi A, Silvagni E, Govoni M, Giuggioli D.   +7 more
europepmc   +1 more source

Systematic profiling reveals broad G protein coupling and context‐dependent modulation of cyclic AMP by the orphan receptor GPR139

British Journal of Pharmacology, EarlyView.
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov, Hans Bräuner, Alexander Sebastian Hauser   +2 more
wiley   +1 more source

Co-prescription of metformin and glucagon-like peptide-1 receptor agonists and metformin-associated lactic acidosis: A case series. [PDF]

Clin Nephrol Case Stud
Hussain H, Ali M, Lorlowhakarn K, Capistrano MC, Balakrishnan VS, Jaber BL.   +5 more
europepmc   +1 more source

Association Between Glucagon-Like Peptide-1 Receptor Agonists and Clinical Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obesity. [PDF]

Drug Des Devel Ther
Huang SC, Wu JY, Kuo CY, Hsu WH, Tsai YW, Lai CC.   +5 more
europepmc   +1 more source

Glucagon-like peptide-1 receptor agonists in movement disorders: From Parkinson's disease to the broader spectrum - Mechanisms, evidence, and future directions. [PDF]

Clin Park Relat Disord
Dahshan A, Khalil MIM, El-Jaafary SI, Al Yamani A.   +3 more
europepmc   +1 more source

Comparison of Perioperative Glycemic Control in Patients Continuing Versus Temporarily Holding Glucagon-Like Peptide-1 Receptor Agonists or Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists Preoperatively. [PDF]

AACE Endocrinol Diabetes
Trykall CC, Hill SB, James AM, Bagnola AJ, Wyne KL, Handley D, Brower KI.   +6 more
europepmc   +1 more source

Potential Antiarrhythmic Mechanisms of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs). [PDF]

Drug Des Devel Ther
Li J, Fu K, Zhao J, Zou Y, Li L, Huang Q, Long L, Ou X, Lei M, Zhang C, Tan X, Chen T.   +11 more
europepmc   +1 more source